Phase 3 trial milestone: Social media erupted with reactions to REGENXBIO's announcement of positive topline data from its pivotal Duchenne muscular dystrophy gene therapy trial, where the treatment met its primary endpoint with robust microdystrophin expression in nearly all patients. Participants noted functional improvements in a subset followed for a year, positioning it as a potential challenger in the space. Yet, shares tumbled sharply in response.
Regulatory and financial hurdles: Concerns dominated discussions around two serious adverse events, a delayed FDA filing until 2027 amid leadership changes, and a cash runway barely lasting that long. Recent FDA rejection of another program fueled skepticism on accelerated approval prospects, despite management assertions of strong data alignment. Earnings miss further pressured sentiment.
Opportunistic views emerge: Amid the selloff, some highlighted undeniable biomarker-clinical correlations and a promising pipeline including AbbVie partnerships. Traders debated asymmetric risk-reward at current levels, with the market seemingly discounting the DMD asset entirely. Overall tone reflects cautious weighing of breakthroughs against persistent biotech volatilities.
Note: This discussion summary was generated from an AI condensation of post data.
REGENXBIO Insider Trading Activity
REGENXBIO insiders have traded $RGNX stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $RGNX stock by insiders over the last 6 months:
- STEVE PAKOLA (Chief Medical Officer) has made 0 purchases and 2 sales selling 20,433 shares for an estimated $221,738.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
REGENXBIO Hedge Fund Activity
We have seen 81 institutional investors add shares of REGENXBIO stock to their portfolio, and 85 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JPMORGAN CHASE & CO removed 483,746 shares (-12.0%) from their portfolio in Q4 2025, for an estimated $6,965,942
- INVENOMIC CAPITAL MANAGEMENT LP removed 426,904 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $6,147,417
- ACADIAN ASSET MANAGEMENT LLC removed 372,166 shares (-99.1%) from their portfolio in Q1 2026, for an estimated $3,118,751
- REDMILE GROUP, LLC removed 324,585 shares (-6.9%) from their portfolio in Q4 2025, for an estimated $4,674,024
- MORGAN STANLEY added 310,520 shares (+18.2%) to their portfolio in Q4 2025, for an estimated $4,471,488
- STATE STREET CORP added 301,858 shares (+15.2%) to their portfolio in Q4 2025, for an estimated $4,346,755
- VOSS CAPITAL, LP removed 280,000 shares (-48.7%) from their portfolio in Q4 2025, for an estimated $4,032,000
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
REGENXBIO Analyst Ratings
Wall Street analysts have issued reports on $RGNX in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Stifel issued a "Buy" rating on 12/19/2025
- Chardan Capital issued a "Buy" rating on 11/20/2025
To track analyst ratings and price targets for REGENXBIO, check out Quiver Quantitative's $RGNX forecast page.
REGENXBIO Price Targets
Multiple analysts have issued price targets for $RGNX recently. We have seen 6 analysts offer price targets for $RGNX in the last 6 months, with a median target of $25.0.
Here are some recent targets:
- Yi Chen from HC Wainwright & Co. set a target price of $30.0 on 03/09/2026
- Judah Frommer from Morgan Stanley set a target price of $17.0 on 03/06/2026
- Daniil Gataulin from Chardan Capital set a target price of $50.0 on 02/10/2026
- Paul Choi from Goldman Sachs set a target price of $12.0 on 02/10/2026
- Annabel Samimy from Stifel set a target price of $45.0 on 12/19/2025
- Mani Foroohar from Leerink Partners set a target price of $20.0 on 12/15/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
